News
PBYI
9.77
-0.51%
-0.05
Weekly Report: what happened at PBYI last week (0914-0918)?
Weekly Report · 6d ago
Puma Biotechnology Advances Alisertib Combo Trial in Small Cell Lung Cancer
TipRanks · 09/18 16:31
Closing Bell Movers: Steel Dynamics, Nucor down on pre-announcement
TipRanks · 09/17 23:40
Puma Biotechnology starts Phase 2 study of alisertib in small cell lung cancer
TipRanks · 09/17 20:10
Weekly Report: what happened at PBYI last week (0907-0911)?
Weekly Report · 09/14 09:04
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?
NASDAQ · 09/09 15:30
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
Barchart · 09/09 15:11
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise
Seeking Alpha · 09/08 15:07
Weekly Report: what happened at PBYI last week (0831-0904)?
Weekly Report · 09/07 09:04
Weekly Report: what happened at PBYI last week (0824-0828)?
Weekly Report · 08/31 09:04
Weekly Report: what happened at PBYI last week (0817-0821)?
Weekly Report · 08/24 09:04
Puma Biotechnology Earnings Call Signals Profitable Momentum
TipRanks · 08/19 00:11
Weekly Report: what happened at PBYI last week (0810-0814)?
Weekly Report · 08/17 09:04
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript
The Motley Fool · 08/14 14:27
Weekly Report: what happened at PBYI last week (0803-0807)?
Weekly Report · 08/10 09:04
Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades
Simply Wall St · 08/08 02:45
Puma Biotechnology Is Maintained at Hold by TD Cowen
Dow Jones · 08/07 21:18
TD Cowen Maintains Hold on Puma Biotechnology, Raises Price Target to $6
Benzinga · 08/07 21:08
Puma Biotechnology price target raised to $6 from $5 at TD Cowen
TipRanks · 08/07 13:26
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF) and Puma Biotechnology (PBYI)
TipRanks · 08/07 00:20
More
Webull provides a variety of real-time PBYI stock news. You can receive the latest news about Puma Biotechnology Inc through multiple platforms. This information may help you make smarter investment decisions.
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.